Browse > Article
http://dx.doi.org/10.4014/jmb.2203.03006

Pneumococcal Δpep27 Immunization Attenuates TLRs and NLRP3 Expression and Relieves Murine Ovalbumin-Induced Allergic Rhinitis  

Yu, Jae Ik (School of Pharmacy, Sungkyunkwan University)
Kim, Ji-Hoon (School of Pharmacy, Sungkyunkwan University)
Nam, Ki-El (School of Pharmacy, Sungkyunkwan University)
Lee, Wonsik (School of Pharmacy, Sungkyunkwan University)
Rhee, Dong-Kwon (School of Pharmacy, Sungkyunkwan University)
Publication Information
Journal of Microbiology and Biotechnology / v.32, no.6, 2022 , pp. 709-717 More about this Journal
Abstract
Allergic rhinitis (AR), one of the most common inflammatory diseases, is caused by immunoglobulin E (IgE)-mediated reactions against inhaled allergens. AR involves mucosal inflammation driven by type 2 helper T (Th2) cells. Previously, it was shown that the Streptococcus pneumoniae pep27 mutant (Δpep27) could prevent and treat allergic asthma by reducing Th2 responses. However, the underlying mechanism of Δpep27 immunization in AR remains undetermined. Here, we investigated the role of Δpep27 immunization in the development and progression of AR and elucidated potential mechanisms. In an ovalbumin (OVA)-induced AR mice model, Δpep27 alleviated allergic symptoms (frequency of sneezing and rubbing) and reduced TLR2 and TLR4 expression, Th2 cytokines, and eosinophil infiltration in the nasal mucosa. Mechanistically, Δpep27 reduced the activation of the NLRP3 inflammasome in the nasal mucosa by down-regulating the Toll-like receptor signaling pathway. In conclusion, Δpep27 seems to alleviate TLR signaling and NLRP3 inflammasome activation to subsequently prevent AR.
Keywords
${\Delta}pep27$; allergic rhinitis; toll-like receptor; NLRP3 inflammasome;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Boucher D, Monteleone M, Coll RC, Chen KW, Ross CM, Teo JL, et al. 2018. Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity. J. Exp. Med. 215: 827-840.   DOI
2 Sutterwala FS, Haasken S, Cassel SL. 2014. Mechanism of NLRP3 inflammasome activation. Ann. NY Acad. Sci. 1319: 82-95.   DOI
3 Gour N, Wills-Karp M. 2015. IL-4 and IL-13 signaling in allergic airway disease. Cytokine 75: 68-78.   DOI
4 Starkhammar M, Larsson O, Georen SK, Leino M, Dahlen SE, Adner M, et al. 2014. Toll-like receptor ligands LPS and poly (I:C) exacerbate airway hyperresponsiveness in a model of airway allergy in mice, independently of inflammation. PLoS One 9:e104114.   DOI
5 Aryan Z, Holgate ST, Radzioch D, Rezaei N. 2014. A new era of targeting the ancient gatekeepers of the immune system: Toll-like agonists in the treatment of allergic rhinitis and asthma. Int. Arch. Allergy Immunol. 164: 46-63.   DOI
6 Xu H, Shu H, Zhu J, Song J. 2019. Inhibition of TLR4 inhibits allergic responses in murine allergic rhinitis by regulating the NF-κB pathway. Exp. Ther. Med. 18: 761-768.
7 Velasco G, Campo M, Manrique OJ, Bellou A, He HZ, Arestides RSS, et al. 2005. Toll-like receptor 4 or 2 agonists decrease allergic inflammation. Am. J. Resp. Cell Mol. 32: 218-224.   DOI
8 Aryan Z, Rezaei N. 2015. Toll-like receptors as targets for allergen immunotherapy. Curr. Opin. Allergy Clin. Immunol. 15: 568-574.   DOI
9 Schroder NW, Morath S, Alexander C, Hamann L, Hartung T, Zahringer U, et al. 2003. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J. Biol. Chem. 278: 15587-15594.   DOI
10 Fransson M, Adner M, Erjefalt J, Jansson L, Uddman R, Cardell LO. 2005. Up-regulation of Toll-like receptors 2, 3 and 4 in allergic rhinitis. Respir. Res. 6: 100.   DOI
11 Hayashi T, Raz E. 2006. TLR9-based immunotherapy for allergic disease. Am. J. Med. 119: 897.e1-6.   DOI
12 Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D. 1999. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol. 163: 1-5.   DOI
13 Malley R, Henneke P, Morse SC, Cieslewicz MJ, Lipsitch M, Thompson CM, et al. 2003. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc. Natl. Acad. Sci. USA 100: 1966-1971.   DOI
14 Kim BY, Shin JH, Park HR, Kim SW, Kim SW. 2013. Comparison of antiallergic effects of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine in a murine model of allergic rhinitis. Laryngoscope 123: 2371-2377.   DOI
15 Stuck BA, Czajkowski J, Hagner AE, Klimek L, Verse T, Hormann K, et al. 2004. Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial. J. Allergy Clin. Immunol. 113: 663-668.   DOI
16 Kim BG, Ghosh P, Ahn S, Rhee DK. 2019. Pneumococcal pep27 mutant immunization suppresses allergic asthma in mice. Biochem. Biophys. Res. Commun. 514: 210-216.   DOI
17 Kim SH, Jang YS. 2017. The development of mucosal vaccines for both mucosal and systemic immune induction and the roles played by adjuvants. Clin. Exp. Vaccine Res. 6: 15-21.   DOI
18 Seon SH, Choi JA, Yang E, Pyo S, Song MK, Rhee DK. 2018. Intranasal immunization with an attenuated pep27 mutant provides protection from influenza virus and secondary pneumococcal infections. J. Infect. Dis. 217: 637-640.   DOI
19 Yang Z, Liang C, Wang T, Zou Q, Zhou M, Cheng Y, et al. 2020. NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis. Biochem. Biophys. Res. Commun. 522: 61-67.   DOI
20 Small P, Keith PK, Kim H. 2018. Allergic rhinitis. Allergy Asthma Clin. Immunol. 14: 51.   DOI
21 Bauchau V, Durham SR. 2005. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 60: 350-353.   DOI
22 Ha J, Lee SW, Yon DK. 2020. Ten-year trends and prevalence of asthma, allergic rhinitis, and atopic dermatitis among the Korean population, 2008-2017. Clin. Exp. Pediatr. 63:278-283.   DOI
23 van de Veen W, Akdis M. 2019. The use of biologics for immune modulation in allergic disease. J. Clin. Invest. 129: 1452-1462.   DOI
24 Dykewicz MS, Hamilos DL. 2010. Rhinitis and sinusitis. J. Allergy Clin. Immunol. 125: S103-115.   DOI
25 Ryu JH, Yoo JY, Kim MJ, Hwang SG, Ahn KC, Ryu JC, et al. 2013. Distinct TLR-mediated pathways regulate house dust mite-induced allergic disease in the upper and lower airways. J. Allergy Clin. Immunol. 131: 549-561.   DOI
26 Kersten G, Hirschberg H. 2007. Needle-free vaccine delivery. Expert. Opin. Drug Deliv. 4: 459-474.   DOI
27 Lee S, Ghosh P, Kwon H, Park SS, Kim GL, Choi SY, et al. 2018. Induction of the pneumococcal vncRS operon by lactoferrin is essential for pneumonia. Virulence 9: 1562-1575.   DOI
28 Kim EH, Choi SY, Kwon MK, Tran TD, Park SS, Lee KJ, et al. 2012. Streptococcus pneumoniae pep27 mutant as a live vaccine for serotype-independent protection in mice. Vaccine 30: 2008-2019.   DOI
29 Giudice EL, Campbell JD. 2006. Needle-free vaccine delivery. Adv. Drug Deliv. Rev. 58: 68-89.   DOI
30 Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group; World Health Organization. et al. 2001. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. 108: S147-334.   DOI
31 Zhong Q, Zhan M, Wang L, Chen D, Zhao N, Wang J, et al. 2021. Upregulation of the expression of Toll-like receptor 9 in basophils in patients with allergic rhinitis: An enhanced expression by allergens. Scand. J. Immunol. 93: e13003.
32 Zhang W, Ba G, Tang R, Li M, Lin H. 2020. Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model. Int. Immunopharmacol. 83: 106394.   DOI
33 Chen CY, Kao CL, Liu CM. 2018. The cancer prevention, anti-inflammatory and anti-oxidation of bioactive phytochemicals targeting the TLR4 signaling pathway. Int. J. Mol. Sci. 19: 2729.   DOI
34 Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, et al. 1992. Cytokine messenger RNA expression for IL-3, IL-4, IL-5, and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. J. Immunol. 148: 2390-2394.   DOI
35 Greenfeder S, Umland SP, Cuss FM, Chapman RW, Egan RW. 2001. Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir. Res. 2: 71-79.   DOI
36 Zhao CC, Xie QM, Xu J, Yan XB, Fan XY, Wu HM. 2020. TLR9 mediates the activation of NLRP3 inflammasome and oxidative stress in murine allergic airway inflammation. Mol. Immunol. 125: 24-31.   DOI
37 Swanson KV, Deng M, Ting JP. 2019. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19: 477-489.   DOI
38 Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, et al. 2009. Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183: 787-791.   DOI
39 Paul WE, Zhu J. 2010. How are T(H)2-type immune responses initiated and amplified? Nat. Rev. Immunol. 10: 225-235.   DOI
40 Caucheteux SM, Hu-Li J, Guo L, Bhattacharyya N, Crank M, Collins MT, et al. 2016. IL-1β enhances inflammatory TH2 differentiation. J. Allergy Clin. Immunol. 138: 898-901.e4.   DOI
41 Goodridge HS, McGuiness S, Houston KM, Egan CA, Al-Riyami L, Alcocer MJ, et al. 2007. Phosphorylcholine mimics the effects of ES-62 on macrophages and dendritic cells. Parasite Immunol. 29: 127-137.   DOI
42 Annunziato F, Romagnani C, Romagnani S. 2015. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 135: 626-635.   DOI
43 Gupta GK, Agrawal DK. 2010. CpG oligodeoxynucleotides as TLR9 agonists therapeutic application in allergy and asthma. BioDrugs 24: 225-235.   DOI
44 Horak F. 2011. VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin. Inv. Drug. 20: 981-986.   DOI
45 Kirtland ME, Tsitoura DC, Durham SR, Shamji MH. 2020. Toll-like receptor agonists as adjuvants for allergen immunotherapy. Front. Immunol. 11:599083.   DOI
46 Thorburn AN, Tseng HY, Donovan C, Hansbro NG, Jarnicki AG, Foster PS, et al. 2016. TLR2, TLR4 and MyD88 mediate allergic airway disease (AAD) and Streptococcus pneumoniae-induced suppression of AAD. PLoS One 11: e0156402.   DOI